97284 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL Framework region [FR]
DOSING REGIMENS USING ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF RHEUMATOID AND PSORIATIC ARTHRITIS
#1502Methods for treating neovascular age-related macular degeneration
#1503Antibody frameworks
#1504Immunologically active polypeptide
#1505Anti-CD38 human antibodies and uses thereof
#1506Monoclonal antibody directed against CXCR5
#1507Antibody molecules to PD-L1 and uses thereof
#1508Immunoglobulin variable region cassette exchange
#1509Compositions and methods for treatment and detection of cancers
#1510Humanization of rabbit antibodies using a universal antibody framework
#1511Neutralizing molecules to influenza viruses
#1512Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF
#1513Binding proteins specific for insulin-like growth factors and uses thereof
#1514Antibody polypeptides that antagonize CD40L
#1515Anti-wall teichoic antibodies and conjugates
#1516Sequence dependent aggregation
#1517Isolation of therapeutic target specific VNAR domains to ICOSL
#1518Therapeutic DLL4 binding proteins
#1519Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#1520Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin
#1521Therapeutic peptides
#1522Heterodimeric immunoglobulins
#1523Antibody molecules to dengue virus and uses thereof
#1524Methods for producing fabs and bi-specific antibodies
#1525CD3 binding domains
#1526Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory
#1527Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
#1528Anti-alpha V beta 6 antibodies and uses thereof
#1529Engineered anti-TGF-beta antibodies and antigen-binding fragments
#1530Aβ protofibril binding antibodies
#1531Method of detecting cleaved SNAP25 in tissue samples
#1532Gram-positive bacteria specific binding compounds
#1533ANTIBODY COMPOSITIONS AND METHODS OF USE
#1534Anti-TAT226 antibodies and immunoconjugates
#1535Anti-wall teichoic antibodies and conjugates
#1536Nucleic acids encoding immunoglobulins that bind TGF-beta receptor II
#1537Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
#1538Humanized monoclonal antibodies against the extracellular domain of human death receptor 5
#1539Modified Antigen Binding Molecules With Altered Cell Signaling Activity
#1540Humanized anti-CD22 antibody
#1541Antibody binding specifically to human and mouse L1CAM protein, and use therefor
#1542Compositions and methods for diagnosing and treating an inflammation
#1543Class I anti-CEA antibodies and uses thereof
#1544Humanized or affinity-matured anti Ang-2 antibody and uses thereof
#1545Chemically modified targeting protein and use thereof
#1546Anti-complement C1s antibodies and methods of inhibiting complement C1s activity
#1547Use of DR6 Antagonists to Improve Motor Neuron Disease
#1548Humanized monoclonal antibodies against activated protein C and uses thereof
#1549Methods of use of anti-CD19 antibodies with reduced immunogenicity
#1550TGF-beta-specific antibodies and methods of use thereof for treatment
#1551Acceptor framework for CDR grafting
#1552Antibodies against factor XII and uses thereof
#1553Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
#1554Anti-PD1 antibodies and their use as therapeutics and diagnostics
#1555Anti-CD79B antibodies and immunoconjugates and methods of use
#1556Biological materials related to c-Met
#1557Anti-blood dendritic cell antigen 2 antibodies and uses thereof
#1558Antibodies to amyloid beta
#1559Antibody capable of specifically recognizing transferrin receptor
#1560Antibodies to surface determinants
#1561Antibodies to TGF-β
#1562Antibodies against human CSF-1R and uses thereof
#1563Antibodies against human CSF-1R and uses thereof
#1564Compositions and methods relating to anti-IGF-1 receptor antibodies
#1565Stable and soluble antibodies inhibiting VEGF
#1566Anti P2Xreceptor antibodies and fragments thereof
#1567Anti-complement C1s antibodies and methods of inhibiting complement C1s activity
#1568T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
#1569Anti-Laminin4 antibodies specific for LG4-5
#1570Anti-CD19 Antibodies
#1571ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
#1572Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE
#1573Anti-jagged antibodies and methods of use
#1574Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
#1575Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
#1576CD3 binding polypeptides
#1577Methods of treating a tauopathy
#1578EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF
#1579Antibody molecules to dengue virus and uses thereof
#1580Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1581Compositions and methods for diagnosing and treating an inflammation
#1582Anti-BAFF antibodies
#1583Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
#1584Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#1585Compounds
#1586Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19
#1587Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
#1588Humanized antibodies to cluster of differentiation 3 (CD3)
#1589Deimmunized serum-binding domains and their use in extending serum half-life
#1590Anti-IL-17A antibodies and their uses
#1591Anti-HSV antibody
#1592Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#1593Antibodies against human CSF-1R and uses thereof
#1594CD33 antibodies and use of same to treat cancer
#1595Anti-Siglec-15 antibodies
#1596Production of T cell retargeting hetero-dimeric immunoglobulins
#1597Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
#1598TNF-ALPHA BINDING PROTEINS
#1599Anti-transferrin receptor antibodies and methods of use
#1600IP-10 antibodies and their uses
#1601ANTI-NOTCH2 NRR ANTIBODIES
#1602Variant immunoglobulins with improved manufacturability
#1603Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
#1604Anti-PD1 antibodies and their use as therapeutics and diagnostics
#1605Methods for binding members of interleukin-4 receptor α (IL-4Rα)
#1606Anti-mesothelin antibodies and immunoconjugates
#1607Antigen binding proteins to Oncostatin M (OSM)
#1608THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
#1609Methods for making fully human bispecific antibodies using a common light chain
#1610Humanized antibodies
#1611Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
#1612Methods for identification of sites for IgG conjugation
#1613Humanized antibodies that recognize alpha-synuclein
#1614Methods of treating a tauopathy
#1615High affinity antibodies that neutralize enterotoxin B
#1616JCV neutralizing antibodies
#1617Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#1618Pseudomonas aeruginosa PCRV binding single variable domain antibodies
#1619Animal models and therapeutic molecules
#1620HA binding agents
#1621Anti-tumor necrosis factor-alpha agents and uses thereof
#1622Methods of inhibiting solid tumor growth by administering GPR49 antibodies
#1623Bispecific chimeric proteins comprising DARPins
#1624Meditopes and meditope-binding antibodies and uses thereof
#1625Humanized antibodies that recognize alpha-synuclein
#1626Antibody polypeptides that antagonize CD40L
#1627Single domain antibodies as inhibitors of PCSK9
#1628Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
#1629Rationally designed, synthetic antibody libraries and uses therefor
#1630Binding molecules specific for HER3 and uses thereof
#1631Anti-wall teichoic antibodies and conjugates
#1632Antibodies to human GDF8
#1633Methods of treating autoimmune diseases by administering monoclonal antibodies against human IL-12
#1634Neutralizing GP41 antibodies and their use
#1635Biological materials related to c-Met
#1636Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#1637Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#1638Anti-B7-H4 antibodies and immunoconjugates
#1639Compositions and methods for diagnosis and treatment of hepatic cancers
#1640Pertuzumab variants and evaluation thereof
#1641Influenza virus antibody compositions
#1642Anti-c-Met/anti-EGFR bispecific antibodies
#1643High affinity, anti-human IgE antibodies
#1644Biological materials related to c-Met
#1645Anti-CD19 antibodies with reduced immunogenicity
#1646Humanized antibodies that recognize alpha-synuclein
#1647Internalizing human monoclonal antibodies targeting prostate and other cancer cells
#1648Immunologically active polypeptide
#1649Gram-positive bacteria specific binding compounds
#1650Serum albumin binding proteins
#1651Prolactin receptor binding proteins and uses thereof
#1652Anti-MCAM antibodies and associated methods of use
#1653Modified proteins and peptides
#1654Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#1655Humanization of rabbit antibodies using a universal antibody framework
#1656Rationally designed, synthetic antibody libraries and uses therefor
#1657Collection and methods for its use
#1658Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#1659TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#1660Stable and soluble antibodies inhibiting TNF alpha
#1661Antibodies against phosphorylcholine
#1662Stable and soluble antibodies inhibiting TNF alpha
#1663Compositions and methods of use for antibodies of Dickkopf-1
#1664Compositions and methods for diagnosing and treating an inflammation
#1665Bispecific antibodies directed against TNF-α and IL-17
#1666Heterodimeric immunoglobulins
#1667Animal models and therapeutic molecules
#1668HA binding agents
#1669Polypeptides, antibody variable domains and antagonists
#1670Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
#1671Antibodies for treatment of cancer
#1672Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
#1673Antibodies recognizing alpha-synuclein
#1674Animal models and therapeutic molecules
#1675Meditopes and meditope-binding antibodies and uses thereof
#1676Anti-CD19 antibodies
#1677Human C-FMS antibodies
#1678Anti-IL13 antibodies and uses thereof
#1679Humanized anti-IL-18 antibodies
#1680Anti-CD79B antibodies and immunoconjugates and methods of use
#1681Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
#1682Therapeutic DLL4 binding proteins
#1683Compositions and methods for the diagnosis and treatment of tumor
#1684Compositions and methods for the diagnosis and treatment of tumor
#1685High affinity antibodies that neutralize enterotoxin B
#1686Transgenic animal for production of antibodies having minimal CDRs
#1687Anti-kit antibodies
#1688Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
#1689Humanized anti-factor D antibodies and uses thereof
#1690Nucleic acids encoding anti-NR10 antibodies
#1691Anti-FGFR4 antibodies and methods of use
#1692Antibodies targeting HIV escape mutants
#1693B-cell reduction using CD37-specific and CD20-specific binding molecules
#1694Stable and soluble antibodies inhibiting VEGF
#1695ST2L antibody antagonists
#1696Soluble heavy-chain only antibodies
#1697Antagonists of IL-17A, IL-17F, and IL-23P19
#1698Engineering of immunoglobulin domains
#1699Single variable domain immunoglobulins that bind TGF-beta receptor II
#1700ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
#1701Anti-FGFR3 antibodies and methods using same
#1702Antibodies to IL-6 and their uses
#1703Humanized antibodies with anti-tumor activity
#1704Humanized EGFR antibodies
#1705Human antibodies to human angiopoietin-like protein 4
#1706Humanized antibodies that recognize alpha-synuclein
#1707Gram-positive bacteria specific binding compounds
#1708Compositions and methods for diagnosing and treating an inflammation
#1709Gram-positive bacteria specific binding compounds
#1710Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#1711Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#1712Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#1713Humanized monoclonal antibodies and methods of use
#1714Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#1715Dual specific binding proteins directed against IL-13 and IL-17
#1716Multispecific deimmunized CD3-binders
#1717Anti-GD2 antibodies
#1718Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
#1719Antibodies directed to αVβ6 and uses thereof
#1720Mice expressing a limited immunoglobulin light chain repertoire
#1721Antibody libraries
#1722High affinity antibodies that neutralize enterotoxin B
#1723Immunobinders directed against TNF
#1724Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same
#1725Biological materials related to HER3
#1726Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
#1727Highly-functional mutant of humanized anti-EGFR antibody variable region
#1728Anti-serum albumin binding variants
#1729Humanized anti-CD19 antibodies
#1730Humanized antibodies that recognize alpha-synuclein
#1731PD-1 antibody
#1732Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#1733Bispecific binding molecules binding to VEGF and ANG2
#1734Sequence dependent aggregation
#1735Humanized anti-EGFL7 antibodies and methods using same
#1736Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin
#1737Anti-HSV antibody
#1738ANTI-VEGF ANTIBODIES
#1739Prevention And Treatment Of Amyloidogenic Disease
#1740Sequence based engineering and optimization of single chain antibodies
#1741High affinity, anti-human IgE antibodies
#1742Anti-FGFR3 antibodies and methods using same
#1743BINDING DOMAINS
#1744Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
#1745ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
#1746METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
#1747METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
#1748Transgenic mouse homozygous for chimeric IgH locus
#1749Targeted binding agents against B7-H1
#1750Class I anti-CEA antibodies and uses thereof
#1751Anti-activin a antibodies and uses thereof
#1752Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#1753TREATMENT WITH ANTI-VEGF ANTIBODIES
#1754Humanization of rabbit antibodies using a universal antibody framework
#1755POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#1756Anti-IL-6 antibodies
#1757Antibodies to lymphotoxin-alpha
#1758Engineered anti-TSLP antibody
#1759Engineered anti-TSLP antibody
#1760Polynucleotides encoding humanized anti-factor D antibodies
#1761CRYSTAL STRUCTURES AND METHODS USING SAME
#1762TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
#1763Antibodies specific for TGF-beta and methods for treating thereof
#1764Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same
#1765USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
#1766BIOLOGICAL PRODUCTS
#1767Compounds
#1768Meditopes and meditope-binding antibodies and uses thereof
#1769Monoclonal antibodies against PCBP-1 antigens, and uses therefor
#1770NUCLEIC ACIDS ENCODING ANTI-IL-23 ANTIBODIES
#1771Antagonists of IL-17A, IL-17F, and IL-23P19
#1772Anti-CGRP compositions and use thereof
#1773WISE BINDING AGENTS AND EPITOPES
#1774Anti P2X7 receptor antibodies and fragments thereof
#1775Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
#1776Prevention and Treatment of Amyloidogenic Disease
#1777Humanized anti-FGF19 antagonists and methods using same
#1778Dual Variable Domain Immunoglobulins and Uses Thereof
#1779Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
#1780Methods of treating psoriasis using IL-17 receptor A antibodies
#1781Antigens Associated with Inflammatory Bowel Disease Including Ulcerative Colitis
#1782Biological materials related to c-Met
#1783Antagonist antibodies and their fab fragments against GPVI and uses thereof
#1784Anti-interferon-α antibodies
#1785Compositions and methods relating to anti-IGF-1 receptor antibodies
#17864-1BB binding molecules
#1787Anti-C5a binding antibodies with high block activity
#1788AX1 PCSK9 antagonists
#1789IP-10 antibodies and their uses
#1790Humanized antibodies against human IL-22RA
#1791Methods for treating conditions associated with c-fms
#1792TNF-α binding proteins
#1793Antigen binding proteins
#1794Anti-mesothelin antibodies and immunoconjugates
#1795Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#1796Anti-IL13 antibodies and uses thereof
#1797Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer
#1798ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES
#1799ANIMAL MODELS AND THERAPEUTIC MOLECULES
#1800SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR